Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors - 28/03/24
Highlights |
• | Immune checkpoint inhibitors can lead to acute gastrointestinal immune-related adverse events. |
• | Chronic gastrointestinal immune-related adverse events exist after immune checkpoint inhibitors use. |
• | We describe here 14 patients with endoscopic and/or histological gastrointestinal inflammation persisting at least six months after the last dose of immune checkpoint inhibitors. They received medical treatment or underwent surgery. |
Abstract |
Background and aims |
Immune checkpoint inhibitors (ICI) cause acute gastrointestinal (GI) immune-related adverse events (IrAEs). We aimed to report and describe chronic GI IrAEs.
Methods |
We included consecutive patients addressed to a single center between October 2010 and March 2022 for endoscopic and/or histological GI inflammation persisting at least six months after the last dose of ICI.
Results |
Among a total of 178 patients addressed for GI IrAE, 14 met the inclusion criteria (8 %). The median follow-up was 13 months after discontinuation of ICI. The most common symptom was watery diarrhea (54 %). Ten (77 %) patients had colonic involvement and three patients (21 %) had ileal involvement. Ten patients (77 %) had inflammatory lesions, two patients (15 %) had fistulas and one patient had (8 %) a stricture. All patients had lymphoplasmacytic infiltrate and basal plasmacytosis, and seven (54 %) had crypt distortions. Nine patients (69 %) received medical therapy, including five patients treated with vedolizumab, two patients (15 %) underwent intestinal resection. At the last follow-up, seven of the 13 patients were receiving maintenance therapy. Endoscopic lesions persisted one year after discontinuing ICI in 4/6 patients, and two years after discontinuation in 3/4 patients.
Conclusions |
Chronic GI IrAEs exist after ICI use.
Le texte complet de cet article est disponible en PDF.Keywords : Immunotherapy, Immune checkpoint inhibitors, Immune-mediated adverse effects, Inflammatory bowel disease
Plan
Vol 48 - N° 4
Article 102311- avril 2024 Retour au numéro
Article précédent
- Social determinants of health influencing the adherence to post-endoscopic mucosal resection surveillance
- Bijal Vashi, Dalton A. Norwood, Rebecca Sullivan, Yassmin Hegazy, Sergio A. Sánchez-Luna, Patricia Ajayi-Fox, Ali M. Ahmed, Kondal R. Kyanam Kabir Baig, Shajan Peter, Ramzi Mulki
- Construction and validation of classification models for predicting the response to concurrent chemo-radiotherapy of patients with esophageal squamous cell carcinoma based on multi-omics data
- Zhi-Mao Li, Wei Liu, Xu-Li Chen, Wen-Zhi Wu, Xiu-E. Xu, Man-Yu Chu, Shuai-Xia Yu, En-Min Li, He-Cheng Huang, Li-Yan Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?